Paper Details
- Home
- Paper Details
Original Abstract of the Article :
The fixed association of atorvastatin, perindopril and amlodipine was recently launched by the firm SERVIER under the name of Lipertance®. It is the first fixed association of a statin, an ACE inhibitor and a calcium blocker present on the Belgian market to handle the risk factors that are hypertens...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元：
https://pubmed.ncbi.nlm.nih.gov/28892318
データ提供：米国国立医学図書館（NLM）
Lipertance®: A Triple Threat Against Cardiovascular Risk
The quest for cardiovascular health is a constant journey, with researchers constantly seeking new strategies to combat heart disease. This research focuses on Lipertance®, a new fixed-dose combination of atorvastatin, perindopril, and amlodipine, designed to address the intertwined risks of hypertension and dyslipidemia. The authors highlight the potential benefits of this triple combination, drawing upon the findings of the ASCOT trial, which demonstrated the efficacy of this approach in reducing morbidity and mortality. The study emphasizes the potential synergy of these three agents and the potential for improved patient adherence with a fixed-dose combination.
Lipertance®: A Multifaceted Approach to Cardiovascular Health
The study underscores the potential benefits of Lipertance® in managing cardiovascular risk. This triple combination therapy has the potential to reduce morbidity and mortality by targeting both hypertension and dyslipidemia. The authors suggest that the synergy of these three agents may provide a greater protective effect than individual therapies, like a well-coordinated caravan traversing a challenging desert landscape.
Improving Adherence: A Smooth Journey Towards Health
The study emphasizes the potential for improved patient adherence with Lipertance®. This fixed-dose combination eliminates the need for multiple medications, simplifying the medication regimen and potentially improving compliance. This simplified approach, like a well-paved road through the desert, can make the journey towards cardiovascular health smoother and more manageable for patients.
Dr.Camel's Conclusion
This research presents a promising new approach to managing cardiovascular risk. Lipertance® offers a triple threat against hypertension and dyslipidemia, potentially improving patient outcomes. Like a camel carrying a valuable cargo, this medication has the potential to deliver a healthier future for patients.
Date :
- Date Completed 2018-10-10
- Date Revised 2018-12-02
Related Literature
French
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.